Ethyl 5-bromobenzofuran-2-carboxylate

We are Ethyl 5-bromobenzofuran-2-carboxylate CAS:84102-69-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  Ethyl 5-bromobenzofuran-2-carboxylate
CAS.NO: 84102-69-2
Synonyms:
ethyl 5-bromo-1-benzofuran-2-carboxylate

Molecular Formula: C11H9BrO3
Molecular Weight:269.091

Physical and Chemical Properties:
Density: 1.52g / cm3
Boiling point: 328.3ºC at 760 mmHg
Melting point: 60-62ºC
Flash point: 152.4ºC
Refractive index: 1.599

Specification:
Appearance: Light yellow solid powder
Purity:≥99%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Refrigerator.Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Veratrazodone hydrochloride CAS:163521-08-2

Ethyl 5-bromobenzofuran-2-carboxylate


Related News: Inceptua is a pharmaceutical company and service partner spanning throughout the product lifecycle – from comparator sourcing for clinical trials, through early access programs to licensing and commercialization for products.2-desoxi-2,2-difluoro-D-ribofuranosa-3,5-dibenzoato CAS:143157-22-6 With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs.6-chloroguanine CAS:10310-21-1 With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs.6940-49-4 “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).

Related Products
Product Name
phloroglucinol View Details
6-Chloroimidazo[1,2-b]pyridazine View Details
3,5-Dimethylbenzonitrile View Details
2-Acetylpyridine manufacturer 1-Benzyl-3-piperidone hydrate hydrochloride manufacturer L-Homophenylalanine manufacturer 4-(4-bromophenyl)dibenzofuran manufacturer 5,7-Dihydro-5-phenylindolo[2,3-b]carbazole manufacturer